Laboratory research that studies blood and tissue with and without cancer helps scientists understand how cancer develops. This knowledge opens possibilities for new approaches to treating and preventing cancers. Clinical trials test these new approaches under strict safety controls to help doctors discover the best treatments possible.
The following Hereditary Gastrointestinal Cancer Registry research studies and clinical trials are now enrolling.
Molecular Signature of Colon Cancer Risk
This study compares the molecular (genetic) messages in colon tissue from people with and without an inherited risk for colon cancer. It also examines the changes in the molecular messages that occur over time as polyps and cancer develops in colon tissue.
This study's goal is to obtain data that could lead to a new diagnostic test for people at increased risk for colon cancer. The study may also identify important biologic processes for which specific new drugs to treat and prevent colon cancer can be developed.
Participants must be 18 years or older and undergoing endoscopy as part of regular care through University of Utah's gastroenterology clinics. We are enrolling patients with inherited colon cancer conditions and controls. Please remove flyer link
Pediatric Phase III Placebo-Controlled Trial of Celecoxib in Genotype Positive Subjects with Familial Adenomatous Polyposis
This clinical trial involves children age 10 to 17 years who have been diagnosed with familial adenomatous polyposis (FAP) or are at risk due to their family history. Celecoxib has been shown to reduce polyps in adults with FAP. This study examines whether celecoxib can stabilize or reduce the size and number of adenomatous polyps to delay or prevent colectomy (removal of all or part of the bowel) in children.
Molecular Classification of Cancer (Pancreas)
This study involves collection and comparison of tissue and blood from people with and without pancreas cancer to help understand, treat, and prevent the disease. Anyone over age 18 can participate. Patients, family members, and friends can contribute blood samples.
Pilot Study of Sulindac/EGFR-Inhibitor in AFAP Patients with Duodenal Polyps
This clinical trial investigates whether the combination of two drugs, erlotinib and sulindac, is safe and effective in reducing polyp size and development in people who have duodenal and colorectal polyps due to familial adenomatous polyposis (FAP) or attenuated familial adenomatous polyposis (AFAP).
To learn more about this study, please see the study flyer by clicking study flyer.
FAP Mutation-Negative Study
HGCR participants who are diagnosed with FAP or AFAP are eligible if:
- ?They have had clinical genetic testing for the APC gene and
- No mutations were found
Participants may have their blood tested again to possibly identify another mutation. If information is found that would be helpful for the participant to know, HGCR will contact the participant and offer further testing on a fresh blood sample.